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The main challenge of vaccine control of poliomyelitis in the 1980s is in the subtropical and
tropical regions of the world where "lameness" surveys in recent years have shown how very
high the average annual incidence of paralytic poliomyelitis can be in both rural and urban
areas in the absence of epidemics. The procedures by which oral polio vaccine (OPV) rapidly
eliminated all or almost all paralytic disease caused by polioviruses from the economically
developed temperate climate countries have been inadequate in tropical and subtropical coun-
tries, except in some small countries with good health services, largely because there is much
more year-round circulation of"wild" polioviruses which continue to produce the disease in the
unvaccinated and incompletely vaccinated children. Not even a cheap, hypothetically 100 per-
cent effective, one-dose vaccine could eliminate poliomyelitis in the tropics if, for a variety of
reasons, it would reach only a portion of the infant population. Paralytic disease caused by
polioviruses has been quickly eliminated from both small and large tropical countries by OPV
in well-organized programs of annual mass vaccinations of almost all children under a certain
age.
FOREWORD
In 1961, Dorothy Horstmann was the guest editor of a Festschrift for John R. Paul on the occasion of
his retirement as chairman of the Department of Preventive Medicine of the Yale University School of
Medicine. It was in this department, which Dr. Horstmannjoined 40 years ago, that she has been making
her outstanding contributions to our understanding ofpoliomyelitis and other human viral diseases. And
now it is her turn for a Festschrift, in which I am happy to be one ofthe contributors and also to wish her
many more years of happiness in her work and personal life.
The Yale Poliomyelitis Unit, with John R. Paul and James D. Trask, was founded in 1931, the year of
severe poliomyelitis epidemics in New York City and New Haven, the year I graduated from the New
York University College ofMedicine, the year I began to work on poliomyelitis, the year I first met Paul
and Trask, the year in which my own highly rewarding close relationship with these two outstanding in-
vestigators began. Shortly after Jim Trask's tragic premature death in May 1942, Dorothy Horstmann
joined the Yale Poliomyelitis Unit-and we have shared common interests and a warm personal relation-
ship ever since then. For some reason, I cannot forget one episode in 1943 when as a major in the U.S.
Army, just returned from Egypt, I participated along with John Paul, Dorothy Horstmann, and other
members ofthe club in a meeting ofthe Virus Commission ofthe Army Epidemiological Board. After the
meeting we all went to dinner and enjoyed among other things dancing to good music. While Dorothy
Horstmann and I were having fun on the dance floor, I was tapped on the shoulder by one of her young
associates, a recently commissioned lieutenant, who said to me: "Major, take it easy." It has taken me a
long time to heed his warning, but I am ready to do it now, and before I retire at the end of June 1982, I
will speak my mind on "Vaccine Control of Poliomyelitis in the 1980s," the topic assigned to me by the
Festschrift Committee.
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All rights of reproduction in any form reserved.The issues and challenges in the prevention of persisting paralytic disease caused
by polioviruses are different in the temperate climate countries with limited seasonal
dissemination of polioviruses and in the subtropical and tropical countries with ex-
tensive year-round dissemination of polioviruses.
ISSUES AND CHALLENGES IN TEMPERATE CLIMATE COUNTRIES
Countries Using Exclusively Oral Polio Vaccine (OPV)
OPV has been used exclusively in temperate climate countries with a combined
total population of almost 2,000 million people, including China, the USSR, the
U.S.A., Japan, and many smaller countries in Europe, the Americas, and Oceania.
The vaccination programs in these countries have varied considerably in the extent
of vaccine coverage in initial national or regional mass campaigns for rapidly break-
ing the chain of transmission of"wild" polioviruses as well as in subsequent vaccina-
tion of the oncoming generations of children; the continuous importation of "wild"
polioviruses from adjacent regions or countries has also varied. Accordingly, it is
not surprising that the extent to which paralytic poliomyelitis caused by polioviruses
has been controlled in these countries has also varied from complete since 1960 (e.g.,
Czechoslovakia, East Germany) and almost complete in recent years (e.g., U.S.A.,
Japan, most of the USSR, most European countries, Australia, New Zealand, etc.)
to extensive reduction in much of China.
In the U.S.A., the average estimated number ofnonpersisting and persisting cases
of paralytic poliomyelitis was 135 per million total population per year during the
pre-vaccine period of 1951-1955, an average of 26 mostly persisting paralytic cases
per million total population per year during the five years of 1956-1960 when only
inactivated polio vaccine (IPV) was used, and only an average of 4 per 100 million
total population per year during the six years of 1973-1978, when only OPV was
used [1]. The very small number of reported cases in 1973-1978 included imported
cases as well as cases whose poliovirus etiology is, in my judgment, in doubt. My
analysis of previously published data [2-4] indicated the dubious etiology of the
rare "vaccine-associated," "family contact," "community contact," or "immuno-
deficient" cases. Recently I also reported the isolation of polioviruses from a
variety of paralytic cases in Brazil, initially reported as poliomyelitis, and subse-
quently found not to be poliomyelitis, and indicated the clinical and clinical
laboratory findings that are not compatible with a definite diagnosis of a paralytic
disease as poliomyelitis [1]. The total number of reported cases for a total popula-
tion of about 230 million was six in 1980 and six in 1981, i.e., an average of 2.6/100
million/year in the U.S.A.
It is noteworthy that this extraordinary elimination of paralytic poliomyelitis
from the U.S.A. has been achieved despite (a) the large number of economically
deprived one- to four-year-old children who have had no vaccine at all and the still
larger number who had less than three doses [1] and (b) the continuous annual im-
portation of "wild" polioviruses by thousands of Mexican families with small
children.
If currently available more potent IPV would replace OPV in the U.S.A. as some
are proposing [5], the benefits derived from the current break in the chain of
transmission ofimported "wild" polioviruses and from the contact immunization of
unvaccinated children [1] would disappear in due time, and the unvaccinated and
those who lost their IPV-acquired immunity would again face the danger of
paralytic disease caused by polioviruses.
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Countries Using Exclusively IPV
There is no question that more potent IPV, especially as used in multiple doses, in
almost 100 percent of children in Sweden [6], Finland [7], and Holland [8] can pro-
tect against paralytic poliomyelitis caused by polioviruses. As I have previously
pointed out [1] paralytic poliomyelitis did not disappear quickly in these countries as
it did in many countries after the initial mass campaign with OPV, and the reason
for the marked reduction or suggested complete elimination of circulating
polioviruses is not entirely clear.
Thus, in Finland (population, 4-5 million) with extensive use of IPV since 1957,
there were 302 paralytic cases reported in 1959, and 273 cases in 1960. And then,
remarkably, no cases have been reported since 1964, despite the fact that an an-
tibody survey in 1964-1966 showed that about 60 percent of children under three
years ofage, i.e., those born afterthe 1959 and 1960 epidemics, had no demonstrable
antibodies to types 1 and 3 polioviruses [9]. According to Lapinleimu and Stenvik
[7] although "97% ofchildren have received complete primary vaccination" (vaccine
used and potency not mentioned), a serological survey of preschool children in
1972-1974 showed that antibodies were not demonstrable for type 1 in 30-40 per-
cent, for type 3 in 50 percent, and for type 2 in 10-20 percent. Moreover, the an-
tibody titers before the booster dose at school entry were very low-"about 1:4 to
type 3 and 1:8 to type 1." And yet an intensified search for polioviruses in 1972-1974
in 309 cases of aseptic meningitis, encephalitis, and transient paralysis, in fecal
samples from 4,878 healthy preschool children, and in weekly samples of sewage
from Helsinki yielded not a single poliovirus but many other enteroviruses.
Lapinleimu and Stenvik [7] concluded: "Experiences in Finland show that low and
even undetectable antibodies protect people from poliomyelitis and even eliminate
polio viruses from the country, provided that nearly all children have been vac-
cinated." This conclusion on transmission ofpolioviruses and protection ofchildren
who lost IPV-induced antibody is not in accord with a great deal of data on the
multiplication of OPV strains and naturally occurring polioviruses in persons with
only IPV-acquired antibody or the occurrence of paralytic poliomyelitis in persons
with four or more doses of killed vaccine(177 cases in 1959 in the U.S.A.). There must
be some other explanations for these findings in Finland, among them that extensive
rapid mass vaccinations with OPV in most ofEurope by 1964 greatly reduced the in-
troduction of "wild" polioviruses in neighboring countries.
The control of paralytic poliomyelitis in Sweden is unquestionably due to the ex-
tensive vaccination of nearly 100 percent of the susceptible age groups with many
doses of potent IPV [6]. Although the antibody status of preschool children in
Sweden is much better than in Finland, the remarkable disappearance of detectable
polioviruses may have the same explanation as in Finland, and cannot be attributed
to the IPV-induced antibodies [1].
In Holland, where nearly 100 percent of children (excepting certain religious
groups) have for many years received many doses of more potent IPV [8], the
average annual incidence of about 11 paralytic cases per 100 million during the ten-
year period of 1966-1975 is about three times more than was reported in the U.S.A.
during the six-year period of 1973-1978 [1]. Recent reports by Bijkerk et al. [10] and
by Kapsenberg et al. [11] indicated that during the 1978 "wild" type 1 poliovirus
epidemic in unvaccinated persons, fully vaccinated healthy schoolchildren also ex-
creted the type 1 epidemic strain, and that type 3 and type 2 polioviruses were also
being disseminated in Holland, as indicated by the finding of type 3 and type 2 an-
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religious groups opposed to vaccination. Yet, examination of 19,416 fecal samples
from 0-4-year-old children entering kindergartens and day nurseries in Amsterdam
over a period of 15 consecutive years (1963-1977), yielded 613 other enteroviruses
but no polioviruses[11].
Since there are practically no unvaccinated children in Sweden and Finland, the
more sensitive serologic survey test for dissemination of polioviruses cannot be used
there. As part of a more detailed discussion of "herd immunity" in Sweden and
Finland, I previously pointed out [1] that in the prevaccine era in Sweden, even a
serologic survey of 200 children failed to detect dissemination of polioviruses for as
long as five years after an epidemic.
ISSUES AND CHALLENGES IN SUBTROPICAL
TROPICAL COUNTRIES
New Perspectives on Incidence ofPoliomyelitis in the Tropics
Although it had long been suspected that the number of officially reported cases
of paralytic poliomyelitis in the tropics was an inadequate measure of the real in-
cidence of the disease, it was the "lameness surveys" in Ghana in 1974 [12,13] that
first indicated the real magnitude oftheproblem ofpersisting paralytic poliomyelitis
in rural and urban areas in the absence of epidemics. The minimal average, annual
incidence of 235-280 cases of persisting paralytic poliomyelitis per million total
population, which could be estimated from the prevalence of residual paralytic
poliomyelitis in Ghana, was much higher than the average annual rate of 135
reported cases of persisting and nonpersisting cases per million in the last five years
(1951-1955) ofthe prevaccine era in the U.S.A. [1] and of 170 per million in Sweden
[6]. Subsequent surveys for residual paralytic poliomyelitis in Burma, Egypt, Philip-
pines, Thailand, Indonesia, Malawi, Ivory Coast, and Brazil (summarized in [1])
and also in India, Yemen, United Republic ofCameroon, and Niger, reported in the
World Health Organization Weekly Epidemiological Record of 1981 (56:131, 297,
397) and 1982 (57:4), have yielded varying but similar results. These accumulated
data have demolished the old dogma about poliomyelitis in the tropics (still being
repeated byexperts), i.e., that while the infection rate with polioviruses was high the
paralytic rate was low, and that an increased incidence of the paralytic disease was
related to emerging epidemics and an improvement in the standard of living
reflected in diminishing infant mortality rates.
These new data have shown us in a most vivid manner that the main challenge to
the vaccine control ofparalytic poliomyelitis caused by polioviruses in the 1980s is in
the subtropical and tropical regions of the world, where the major part of the world
population lives in poverty, and where shortage of food, inadequate housing, water
supplies, sanitary facilities, and sewage disposal are the main causes of poor health
and debility; i.e., the part of the world that presents the greatest challenge to ad-
vance public health by the simplest possible procedures before economic develop-
ment makes it possible to copy the procedures of the economically developed coun-
tries in the temperate climate zones.
Vaccine Control of Poliomyelitis in the Tropics and Subtropics
In some small subtropical and tropical countries, e.g., Puerto Rico, Panama,
Singapore, andHongKong, withgood healthservices, goodcontrol ofpoliomyelitis
has been achievedby extensive routine vaccination ofalmost all children with OPV.
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In 1979, I analyzed the problem of elimination of paralytic poliomyelitis caused by
polioviruses from econmically underdeveloped countries with inadequate health ser-
vices and concluded that the problem was administrative and not immunological or
epidemiological [14]. It was evident that the problem was not with the immunogenic-
ity ofOPV in these countries, as was assumed by the investigators who were selected
to participate in the 1980 International Symposium on Reassessment of Inactivated
Poliomyelitis Vaccine in Bilthoven, Holland [15], but rather that the procedures of
using OPV that were so highly effective in the temperate climate countries had to be
modified in parts of the world where paralytic polioviruses are propagating
throughout the year in a very large proportion of the infant population, even as
early as the first month of life. It became evident to me almost 20 years ago that initial
mass vaccination programs with OPV followed by routine vaccination concurrently
with other vaccines routinely administered as part of regular health care during the
first year of life which brought about such dramatically rapid elimination of the
disease in many large and small temperate climate countries, had only a temporary
impact in tropical countries, largely because a single mass campaign reaching even
90 percent or more of susceptible children only temporarily suppresses the circula-
tion of "wild" polioviruses and also because subsequent routine vaccination pro-
grams at best reached only 20-40 percent of the total infant population. Under such
conditions, even a hypothetical vaccine that would provide lifelong immunity in a
single dose to 100 percent of children receiving it early in life could at best only
reduce the incidence of the disease.
Twenty years ago, Cuba was the first country to introduce the procedure of na-
tional, annual mass vaccination campaigns with OPV on two Sundays ofthe year of
all children under five years ofage, regardless ofhow many doses they may have had
before, with a rapid and lasting elimination of the disease [16]. In 1968, Dorothy
Horstmann and I, as consultants to the Pan American Health Organization, recom-
mended a similar program for other Latin American countries, but despite my re-
peated recommendations [3,14] Brazil and Mexico have only recently adopted this
procedure. The particular point in such annual national mass vaccinations with
OPV is not only that the special organization of large numbers of nonprofessional
personnel makes it possible to reach an extraordinarily high proportion of all
children even in remote areas of large countries, but that most of the vaccination is
carried out in one or two days which rapidly establishes a dominant circulation of
the attenuated vaccine strains in the community [17]. When vaccination of children
is spread out over a long period of time, as each one reaches the age of routine vac-
cination, the "wild" polioviruses and other enteroviruses that are so extensively
disseminated in subtropical and tropical regions remain the dominant viruses in the
community. This is another reason why the World Health Organization Expanded
Immunization Programme, which is patterned after polio immunization programs
of the temperate climate, developed countries will remain only partly effective in the
undeveloped, tropical countries, even after the goal of routine vaccinations of a
larger proportion of the children has been achieved.
In 1980 and 1981, Brazil has shown how a geographically huge country can suc-
cessfully organize a huge, standing army of nonprofessional volunteers to bring
OPV to almost all children under five years of age (over 18 million) in annual, na-
tional mass campaigns carried out almost entirely on a single day twice a year, with
an interval of two months. The 1980 program was carried out in June and August,
and the 1981 program in August and October. There was a precipitous drop in
reported cases [181. A personal analysis ofthe small number ofcases reported in five
387months after the 1980 campaign showed that 76 percent were not compatible with a
clinical diagnosis ofparalytic poliomyelitis by strict criteria, and that many paralytic
cases which clinically were not poliomyelitis excreted polioviruses in their feces and
had evidence of concurrent infection with polioviruses [1]. In August 1981, I ana-
lyzed the 35 cases that had been reported since the beginning ofthe year in the states
of Sao Paulo, Minas Gerais, and the Distrito Federal before the second national
campaign, and found that, with the possible exception of one case of transitory
paralysis, the other paralytic cases did not fulfill the strict criteria for a clinical
diagnosis of poliomyelitis (unpublished observations). In Mexico, there were five-
day national mass vaccination campaigns in 1981 and 1982 which reached about 80
percent ofchildren under five years ofage (personal communication from Dr. Jorge
Fernandez de Castro, Director General of Epidemiology, Ministry of Health, Mex-
ico). In June and August 1982, Brazil again vaccinated most of the children under
five years of age.
In subtropical and tropical countries there are many more paralytic conditions
that clinically closely resemble poliomyelitis but which pathologically are not and
which exhibit certain clinical and clinical laboratory findings that can distinguish
them from paralytic poliomyelitis caused by enteroviruses [1]. In 1969, my
associates and I [191 reported that in Mexico 45 percent of 57 fatal cases ofparalytic
disease, clinically diagnosed as paralytic poliomyelitis, were found not to be polio-
myelitis but three varieties of noninflammatory pathological neuronal syndromes-
Guillain-Barre infectious polyneuritis (10 cases), cytoplasmic neuronopathy (8
cases), and nuclear neuronopathy (7 cases) with type 1 poliovirus in the feces and in-
testinal tract of one of the latter. In 1971, Valenciano et al. [20] described an out-
break of 25 cases of lower motoneuron paralytic illness withoutfever, pleocytosis,
or increased CSFprotein in Albacete, Spain. Postmortem findings in three of the
five fatal cases also showed no inflammatory reaction in the nervous system, with
changes comparable to cytoplasmic neuronopathy in at least one case. It is note-
worthy that while the surviving patients ultimately recovered completely without
atrophy, it occasionally took eight to ten months, with slight muscle weakness and
hyporeflexia still being present in a few one year after onset.
It is clear, from what has just been said, that as paralytic poliomyelitis caused by
polioviruses is increasingly controlled by vaccination, reported cases of lower moto-
neuron paralytic disease, with and without pleocytosis, must be carefully analyzed,
and that the mere isolation of a poliovirus (vaccine-like or nonvaccine-like) can no
longer per se constitute evidence of its etiologic relationship to the paralytic disease.
It is also clear that cases of lower motoneuron paralytic disease which occur in
children who have had multiple doses of either IPV or OPV or both are very likely
not to be paralytic poliomyelitis caused by polioviruses. I can never forget a front-
page story in a 1963 Colombo, Ceylon (Sri Lanka) newspaper which, during a severe
polio epidemic, asked what good are polio vaccines when a rich man's child who had
seven doses of Salk vaccine and five doses of Sabin vaccine can die ofthe disease. It
turned out that she had died of Guillain-Barre syndrome with typical albumino-
cytological dissociation.
Use ofHighly Immunogenic Potent IPVfor Elimination ofParalytic
Poliomyelitis in the Tropics
There is no question that more potent and very much more expensive IPV can be
highly immunogenic and after multiple doses can produce very high titers of anti-
body that will persist for longer periods oftime. However, as long as a large propor-
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tion of children receive either no vaccine at all or only one dose, IPV cannot be
expected to accomplish more than OPV and, for a variety of other reasons, not as
much. Melnick's recent recommendation [21] that multiple doses of IPV and OPV
be used in routine vaccination as a means of eliminating paralytic poliomyelitis in
the tropics is, in myjudgment, based not only on an improper evaluation ofthe con-
tinuing greater incidence of paralytic disease among Arab children in Israel, the
West Bank, and the Gaza strip than among Jewish children in Israel, but also on a
disregard of the procedure by which OPV produces its maximum effect in such
populations. He also failed to appreciate the impracticality of his proposal for im-
poverished populations with limited health services.
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